FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 333:664-665 September 7, 1995 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, widely prescribed to treat hypercholesterolemia, are clearly effective and are associated with reductions in mortality from coronary disease and overall mortality.¹ Toxic effects on skeletal muscle, which may range from diffuse myalgia to severe rhabdomyolysis, are a known side effect of these drugs.² Interactions of HMG-CoA reductase inhibitors with cyclosporine, and less often with gemfibrozil and niacin, increase the risk of rhabdomyolysis.² We report a case of severe rhabdomyolysis from the coadministration of lovastatin, niacin, and itraconazole.

A 63-year-old woman with familial hypercholesterolemia and a previous myocardial infarction who had . . . [Full Text of this Article]

References

This article has been cited by other articles:

• HERSH, E. V., MOORE, P. A. (2004). Drug interactions in dentistry: The importance of knowing your CYPs. Journal of the American Dental Association 135: 298-311 [Abstract] [Full Text]  
• Shaukat, A., Benekli, M., Vladutiu, G. D, Slack, J. L, Wetzler, M., Baer, M. R (2003). Simvastatin-Fluconazole Causing Rhabdomyolysis. The Annals of Pharmacotherapy 37: 1032-1035 [Abstract] [Full Text]  
• Kuroha, M., Azumano, A., Kuze, Y., Shimoda, M., Kokue, E. (2002). Effect of Multiple Dosing of Ketoconazole on Pharmacokinetics of Midazolam, a Cytochrome P-450 3A Substrate in Beagle Dogs. Drug Metab. Dispos. 30: 63-68 [Abstract] [Full Text]  
• Davidson, M. H. (2001). Treatment of the Elderly with 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitors: Focus on Drug Interactions. J CARDIOVASC PHARMACOL THER 6: 219-229 [Abstract]  
• Bottorff, M., Hansten, P. (2000). Long-term Safety of Hepatic Hydroxymethyl Glutaryl Coenzyme A Reductase Inhibitors: The Role of Metabolism--Monograph for Physicians. Arch Intern Med 160: 2273-2280 [Full Text]  
• Sharobeem, K. M., Madden, B. P., Millner, R., Rolfe, L. M., Seymour, C. A., Parker, J. (2000). Acute Renal Failure After Cardiopulmonary Bypass: A Possible Association With Drugs of the Fibrate Group. J CARDIOVASC PHARMACOL THER 5: 33-39 [Abstract]  
• Herman, R. J. (1999). Drug interactions and the statins. CMAJ 161: 1281-1286 [Abstract] [Full Text]  
• Fischer, V., Johanson, L., Heitz, F., Tullman, R., Graham, E., Baldeck, J.-P., Robinson, W. T. (1999). The 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor Fluvastatin: Effect on Human Cytochrome P-450 and Implications for Metabolic Drug Interactions. Drug Metab. Dispos. 27: 410-416 [Abstract] [Full Text]  
• Ballantyne, C. M., von Moltke, L. L., Greenblatt, D. J., Kobashigawa, J., Keogh, A. M., Spratt, P., Valantine, H. A. (1996). Drugs in Cardiac Transplantation. NEJM 334: 400-402 [Full Text]